Please assess the completion status of the following clinical trial:

Trial Title: Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age, LV EF \< 40%~Exclusion Criteria:~* long-term use of medications that inhibit cytochrome P450 3A4.~* inability patients with exercise test~* primary pulmonary artery hypertension~* severe hypotension (\< 90/50mmHg) or severe hypertension (\> 170/100mmHg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- placebo arm (Type: PLACEBO_COMPARATOR): Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
- Udenafil (Type: ACTIVE_COMPARATOR): Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).